Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 10/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | GLP1R | P43220 | 4/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24024088 | 0.98 | PTH1R (0.59) | PTH1RRXFP1GLP1RKISS1RKEAP1 | |
| SCHEMBL24024100 | 0.95 | KISS1R (0.63) | PTH1RRXFP1KISS1R | |
| SCHEMBL24024101 | 0.94 | GLP1R (0.59) | PTH1RRXFP1GLP1RKISS1RKEAP1 | |
| SCHEMBL24024085 | 0.93 | RXFP1 (0.65) | PTH1RRXFP1GLP1RKISS1R | |
| SCHEMBL29760958 | 0.89 | KISS1R (0.57) | PTH1RRXFP1GLP1RKISS1RKEAP1 | |
| SCHEMBL31135025 | 0.89 | PTH1R (0.68) | PTH1RRXFP1GLP1RKISS1R | |
| SCHEMBL29555128 | 0.88 | GLP1R (0.66) | RXFP1GLP1RKISS1R | |
| SCHEMBL30874394 | 0.87 | RXFP1 (0.67) | PTH1RRXFP1GLP1R | |
| SCHEMBL30874405 | 0.87 | RXFP1 (0.64) | PTH1RRXFP1GLP1R | |
| SCHEMBL29880080 | 0.86 | PTH1R (0.64) | PTH1RGLP1RKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355186-A1 | GLP-1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355186-A1 | GLP-1 RECEPTOR ANTAGONISTS | GLP1R, GIPR, GPR119 | PTH1R 143/4885RXFP1 8/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.